Dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
=== Pharmacodynamics === Oxymorphone elicits its effects by binding to and activating the μ-opioid receptor (MOR) and, to a much lesser extent, the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). Its activity at the DOR may augment its action at the MOR. Oxymorphone is 10 times more potent than morphine. 1.02 mg of oxymorphone hydrochloride produces analgesia roughly equivalent to 10 mg of morphine sulfate, with similar peak and duration of effect but potentially slightly fewer side effects at equipotent doses.
== Early years == This hypothesis was first proposed by Jaak Panksepp in a 1979 paper, in which he speculated that autism might be "an emotional disturbance arising from an upset in the opiate systems in the brain". Kalle Reichelt then emerged as one of the leading advocates of this theory, publishing papers alleging that "the patterns of peptides and associated proteins from urinary samples [from people with autism] differ considerably from each other and from normal controls." In addition, Reichelt's research has concluded that autistic individuals have increased levels of these peptides in their cerebrospinal fluid. Additionally, in a 1991 paper, Reichelt argued that gluten and casein may play a causative role in autism, as the incomplete digestion thereof may produce certain opioid peptides. Thus, those, such as Paul Shattock, who advocate this theory also advocate the use of a gluten-free, casein-free diet as a treatment for autism.
== Society and culture == Addiction carries substantial social and economic consequences, is among the more heavily stigmatized health conditions, and has been interpreted through political and anthropological frameworks as well as medical ones.
== History and etymology == Alanine was first synthesized in 1850 when Adolph Strecker combined acetaldehyde and ammonia with hydrogen cyanide. The amino acid was named Alanin in German, in reference to aldehyde, with the interfix -an- for ease of pronunciation, the German ending -in used in chemical compounds being analogous to English -ine.
Sources: en.wikipedia.org
=== Congenital adrenal hyperplasia === In congenital adrenal hyperplasia, the adrenal cortex lacks appropriate corticosteroid synthesis, leading to excess adrenal androgens and affects female fetuses. There is an external masculinization of the genitalia in the female fetuses. Mothers of at risk fetuses are given dexamethasone at 6 weeks gestation to suppress pituitary gland release of androgens. If analysis of cffDNA obtained from a sample of maternal plasma lacks genetic markers found only on the Y chromosome, it is suggestive of a female fetus. However, it might also indicate a failure of the analysis itself (a false negative result). Paternal genetic polymorphisms and sex-independent markers may be used to detect cffDNA. A high degree of heterozygosity of these markers must be present for this application.
==== Turkey ==== Turkish think tanks are relatively new, having emerged in the 1960s. There are at least 20 think tanks in the country, both independent and supported by government. Many of them are sister organizations of political parties, universities or companies some are independent and others are supported by government. Most Turkish think tanks provide research and ideas, yet they play less important roles in policy making than American think tanks. Turksam, Tasam and the Journal of Turkish Weekly are the leading information sources. The oldest and most influential think tank in Turkey is ESAM (The Center for Economic and Social Research; Turkish: Ekonomik ve Sosyal Araştırmalar Merkezi) which was established in 1969 and has headquarters in Ankara. There are also branch offices of ESAM in Istanbul, Bursa, Konya and elsewhere. ESAM has strong international relationships, especially with Muslim countries and societies. Ideologically it performs policies, produces ideas and manages projects in parallel to Milli Görüş and also influences political parties and international strategies. The founder and leader of Milli Görüş, Necmettin Erbakan, was very concerned with the activities and brainstorming events of ESAM. In The Republic of Turkey, two presidents, four prime ministers, various ministers, many members of the parliament, and numerous mayors and bureaucrats have been members of ESAM. The Turkish Economic and Social Studies Foundation (TESEV) is another leading think tank.
=== Sri Lanka === The primary operational ration of the Sri Lanka Armed Forces is the Jungle Ration, a 24-hour ration pack whose components are produced and assembled in Sri Lanka. It is issued to soldiers at the rate of one per soldier per day, and contains both food and sun-dry items designed to sustain troops where food storage and preparation facilities are not practical. All meals are precooked, requiring neither cooking nor preparation, and all items are packaged inside sealed plastic packages or lightweight aluminium cans. Precooked rice is included as part of every meal. Typical contents are: chicken curry with potatoes, vegetable curry, precooked rice, hard crackers, processed cheese, soup cubes, instant milk powder, orange drink powder, and dates or dried pineapple. A sundry pack containing tea bags, sugar, salt, glucose tablets, seasonings, matches, plastic bags, and toilet paper is included with every ration pack.
They suggest that people actively create it and make their lives meaningful by dedicating themselves to what they love. Objectivists contend that meaning does not depend on subjective preferences but is grounded in objective features of reality. Some people seek meaning by promoting concrete general values, like truth, moral goodness, and beauty. Others pursue it in religious practice by trying to realize a supernatural purpose. Further suggested sources of meaning include altruism, creativity, and self-actualization. The inability to find meaning in life can lead to an existential crisis, associated with anxiety and spiritual confusion.
Type I present in liver, kidney, thyroid, and (to a lesser extent) pituitary; it accounts for 80% of the deiodination of T4. Type II present in CNS, pituitary, brown adipose tissue, and heart vessel, which is predominantly intracellular. In the pituitary, it mediates negative feedback on thyroid-stimulating hormone. Type III present in placenta, CNS, and hemangioma. This deiodinase converts T4 into reverse T3, which, unlike T3, is inactive. T4 is synthesised in the thyroid follicular cell as follows.
Sources: en.wikipedia.org
==== Canada ==== In Canada, Pfizer's patent 2,324,324 for Revatio (sildenafil used to treat pulmonary hypertension) was found invalid by the Federal Court in June 2010, on an application by Ratiopharm Inc. On 8 November 2012, the Supreme Court of Canada ruled that Pfizer's patent 2,163,446 on Viagra was invalid from the beginning because the company did not provide full disclosure in its application. The decision, Teva Canada Ltd. v. Pfizer Canada Inc., pointed to section 27(3)(b) of The Patent Act which requires that disclosure must include sufficient information "to enable any person skilled in the art or science to which it pertains" to produce it. It added further: "As a matter of policy and sound statutory interpretation, patentees cannot be allowed to 'game' the system in this way. This, in my view, is the key issue in this appeal." Teva Canada launched Novo-Sildenafil, a generic version of Viagra, on the day the Supreme Court of Canada released its decision. To remain competitive, Pfizer then reduced the price of Viagra in Canada. However, on 9 November 2012, Pfizer filed a motion for a re-hearing of the appeal in the Supreme Court of Canada, on the grounds that the court accidentally exceeded its jurisdiction by voiding the patent. Finally, on 22 April 2013, the Supreme Court of Canada invalidated Pfizer's patent altogether.
=== Addiction === NF-κB is one of several induced transcriptional targets of ΔFosB which facilitates the development and maintenance of an addiction to a stimulus. In the caudate putamen, NF-κB induction is associated with increases in locomotion, whereas in the nucleus accumbens, NF-κB induction enhances the positive reinforcing effect of a drug through reward sensitization.
== Montagnard influence == The working class was especially hurt by a hail storm which damaged grain crops in 1788, which caused bread prices to skyrocket. While the peasants of rural France could sustain themselves with their farms, and the wealthy aristocracy could still afford bread, the urban workers of France, the group that comprised the sans-culottes, suffered. In the city, the division grew between the sans-culottes and these wealthy aristocrats; the former had a particular hostility "towards those with large private incomes." The faction known as the Montagnards expressed concern for the working classes of France. When the National Convention met to discuss the fate of the former king Louis XVI in 1792, the sans-culottes vehemently opposed a proper trial, instead opting for an immediate execution. The moderate Girondin faction voted for a trial, but the radical Montagnards sided with the sans-culottes, deeming that a trial was not necessary, and won with a slim majority. Louis XVI was executed on January 21, 1793. The demands of the sans-culottes did not stop with the execution of the King, and the Montagnards worked hard to fulfil their mounting orders. This increased pressure from the radical masses exacerbated the ideological split between the Montagnards and the Girondins, and tensions began to grow within the convention. Eventually, by May 1793, the Montagnards worked with the National Guard—which was, at this time, mostly sans-culottes—to depose many of the Girondin deputies.
His pair of cleats from the 2000 season were turned in for display at the National Baseball Hall of Fame and Museum. On December 20, 2000, Bagwell and the Astros agreed to a five-year, $85 million (USD, $158.9 million today) contract extension. With an average annual value of $17 million, he became the third-highest paid player in the sport at the time. By 2005, he was the seventh-highest paid player in the sport, receiving $18 million in the fourth year of the deal.
Doxycycline was patented in 1957 and came into commercial use in 1967. It is on the World Health Organization's List of Essential Medicines. Doxycycline is available as a generic medicine. In 2023, it was the 77th most commonly prescribed medication in the United States, with more than 8 million prescriptions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.